Biblio

Author Title [ Type

] Year

Filters: First Letter Of Title is D [Clear All Filters]

Journal Article

Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, et al. DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer. PLoS One. 2013;8(9):e73940.

Yan R, Li JJ, Xiao Z, Fan X, Liu H, Xu Y, Sun R, Liu J, Yao J, An G, et al. DCLK1 suppresses tumor-specific cytotoxic T lymphocyte function through recruitment of MDSCs via the CXCL1-CXCR2 axis. Cell Mol Gastroenterol Hepatol. 2022.

Volk T, Pannicke U, Reisli I, Bulashevska A, Ritter J, Björkman A, Schäffer AA, Fliegauf M, Sayar EH, Salzer U, et al. DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency. Hum Mol Genet. 2015.

Batailler M, Droguerre M, Baroncini M, Fontaine C, Prévot V, Migaud M. DCX expressing cells in the vicinity of the hypothalamic neurogenic niche: A comparative study between mouse, sheep and human tissues. J Comp Neurol. 2013.

Djakbarova U, Marzluff WF, M Köseoğlu M. DDB1 and CUL4 associated factor 11 (DCAF11) Mediates Degradation of Stem-loop Binding Protein at the End of S phase. Cell Cycle. 2016.

Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, Qu M, Zhao W, Yu J, Wang Q-E. DDB2 Suppresses Tumorigenicity by Limiting the Cancer Stem Cell Population in Ovarian Cancer. Mol Cancer Res. 2014.

Ebrahimi KHonarmand, Vowles J, Browne C, McCullagh J, James WS. ddhCTP produced by the radical-SAM activity of RSAD2 (viperin) inhibits the NAD -dependent activity of enzymes to modulate metabolism. FEBS Lett. 2020.

Vella V, Nicolosi MLuisa, Cantafio P, Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A, Malaguarnera R, et al. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. Endocr Relat Cancer. 2018.

Vessella T, Xiang S, Xiao C, Stilwell M, Fok J, Shohet J, Rozen E, H Zhou S, Wen Q. DDR2 signaling and mechanosensing orchestrate neuroblastoma cell fate through different transcriptome mechanisms. FEBS Open Bio. 2024.

Hao J-D, Liu Q-L, Liu M-X, Yang X, Wang L-M, Su S-Y, Xiao W, Zhang M-Q, Zhang Y-C, Zhang L, et al. DDX21 mediates co-transcriptional RNA mA modification to promote transcription termination and genome stability. Mol Cell. 2024.

Sarkar SR, Dubey VKumar, Jahagirdar A, Lakshmanan V, Haroon MMohamed, Sowndarya S, Sowdhamini R, Palakodeti D. DDX24 is required for muscle fiber organization and the suppression of wound-induced Wnt activity necessary for pole re-establishment during planarian regeneration. Dev Biol. 2022.

Su Y-Y, Chao C-H, Hsu H-Y, Li H-K, Wang Y-L, Lee Y-HWu, Mai R-T. DDX3 suppresses hepatocellular carcinoma progression through modulating the secretion and composition of exosome. Am J Cancer Res. 2023;13(5):1744-1765.

Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, Miura S, Watanabe S, Yoshizawa H, Narita I. DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations. PLoS One. 2014;9(10):e111019.

Fu X, Zhang Z, Hayes LR, Wright N, Asbury J, Li S, Ye Y, Sun S. DDX3X overexpression decreases dipeptide repeat proteins in a mouse model of C9ORF72-ALS/FTD. Exp Neurol. 2024:114768.

Rolles B, Meyer R, Begemann M, Elbracht M, Jost E, Stelljes M, Kurth I, Brümmendorf TH, Silling G. DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation. Blood Cancer J. 2023;13(1):73.

Ma J, Mahmud N, Bosland MC, Ross SR. DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice. Stem Cell Reports. 2022.

Potolitsyna E, Pickering SHazell, Tooming-Klunderud A, Collas P, Briand N. De novo annotation of lncRNA HOTAIR transcripts by long-read RNA capture-seq reveals a differentiation-driven isoform switch. BMC Genomics. 2022;23(1):658.

Ranjan A, Ichihashi Y, Farhi M, Zumstein K, Townsley B, David-Schwartz R, Sinha NR. De novo assembly and characterization of the transcriptome of the parasitic weed Cuscuta pentagona identifies genes associated with plant parasitism. Plant Physiol. 2014.

Matsunaga T, Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, Anan T, Mitsuhashi T, Kubota Y, et al. [De novo blast phase of chronic myeloid leukemia with 3q26 abnormality diagnosed by cytogenetic analysis of extramedullary lesion]. Rinsho Ketsueki. 2022;63(12):1643-1647.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, et al. De novo CD5+ Diffuse Large B-cell Lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. Am J Hematol. 2016.

Bui HThi Phuong, Do DHuy, Ly HThi Thanh, Tran KTrung, Le HThi Thanh, Nguyen KTrung, Pham LThi Dieu, Le HDuc, Le VSy, Mukhopadhyay A, et al. De novo copy number variations in candidate genomic regions in patients of severe autism spectrum disorder in Vietnam. PLoS One. 2024;19(3):e0290936.

Yamada Y, Anderson CF, Schneider JP. De Novo Design of a Versatile Peptide-Based Coating to Impart Targeted Functionality at the Surface of Native Polystyrene. ACS Appl Mater Interfaces. 2023.

Mout R, Bretherton RC, Decarreau J, Lee S, Gregorio N, Edman NI, Ahlrichs M, Hsia Y, Sahtoe DD, Ueda G, et al. De novo design of modular protein hydrogels with programmable intra- and extracellular viscoelasticity. Proc Natl Acad Sci U S A. 2024;121(6):e2309457121.

Pereira W, Camps I. De novo design of new inhibitor of mutated tyrosine-kinase for the myeloid leukemia treatment. Curr Pharm Des. 2016.

Yagi M, Kabata M, Ukai T, Ohta S, Tanaka A, Shimada Y, Sugimoto M, Araki K, Okita K, Woltjen K, et al. De Novo DNA Methylation at Imprinted Loci during Reprogramming into Naive and Primed Pluripotency. Stem Cell Reports. 2019.

Pages